👀 Ones to watch: The MOST undervalued stocks to buy right nowSee Undervalued Stocks

Moelis hires former Morgan Stanley bankers for healthcare dealmaking

Published 10/18/2022, 01:29 PM
Updated 10/18/2022, 01:40 PM
© Reuters.
MS
-
TMO
-
DHR
-
MC
-

By David Carnevali

NEW YORK (Reuters) - Moelis (NYSE:MC) & Co. has hired two former Morgan Stanley (NYSE:MS) bankers, Arek Kurkciyan and Dennis Crandall, as managing directors to help drive dealmaking in the life sciences and outsourced pharmaceutical services sectors for the investment bank.

Kurkciyan and Crandall will start their new roles in late November and be based in New York, according to a memo seen by Reuters on Tuesday. Both Kurkciyan and Crandall were managing directors in the healthcare investment banking unit at Morgan Stanley.

"Arek and Dennis bring strong relationships with both large-cap corporates and private equity investors that are core to our Firm's strategy," said Jeff Raich, co-President at Moelis.

In their previous roles at Morgan Stanley, both bankers worked on significant deals involving large healthcare corporations and financial sponsors.

They both jointly worked on deals including the sale of biotech company Aldevron to medical equipment maker Danaher Corp (NYSE:DHR) for $9.6 billion and scientific instruments maker Thermo Fisher (NYSE:TMO)'s acquisition of Brammer Bio for roughly $1.7 billion.

In recent months, Moelis has been attempting to shore up its healthcare M&A unit. It recently hired another senior banker Igor Sokolovsky to help with dealmaking across sectors, with a special focus on healthcare.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.